Carboplatin + paclitaxel + bevacizumab, then bevacizumab maintenance
Checked 2026-09-09
Stage III-IV ovarian cancer, especially with residual disease or ascites
One cycle
every 21 days × 6 · about 18 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Carboplatin Cytotoxic chemotherapy (platinum) | AUC 6 | IV | D1 | |
Paclitaxel Cytotoxic chemotherapy (taxane) | 175 mg/m² | IV | D1 | |
Bevacizumab Monoclonal antibody (anti-VEGF) | 15 mg/kg (7.5 mg/kg in ICON7), from cycle 2 | IV | D1 |
Cycles
6 with chemotherapy; bevacizumab to 15 months (GOG-218) or 12 months (ICON7)
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Not routine
Notes
- PAOLA-1: add olaparib 300 mg twice daily for 2 years in HRD-positive disease.
Used in
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Topotecan
Relapsed SCLC; platinum-resistant ovarian or cervical cancer
every 21 days
BEP
Metastatic germ cell tumour: 3 cycles good risk, 4 cycles intermediate or poor risk
every 21 days × 3
Carboplatin + paclitaxel
Ovarian cancer adjuvant or neoadjuvant (6 cycles); advanced endometrial cancer with pembrolizumab or dostarlimab; NSCLC
every 21 days × 6
Weekly paclitaxel
Platinum-resistant ovarian cancer (with or without bevacizumab); metastatic breast cancer
every 28 days
Pegylated liposomal doxorubicin
Platinum-resistant or partially platinum-sensitive ovarian cancer; Kaposi sarcoma
every 28 days
Olaparib maintenance
Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum
every 28 days × 2
Niraparib maintenance
Newly diagnosed advanced ovarian cancer after platinum response, regardless of BRCA status
every 28 days × 3
Mirvetuximab soravtansine
Folate receptor alpha-high platinum-resistant ovarian cancer, 1-3 prior lines
every 21 days